A Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

NCT ID: NCT02504580

Last Updated: 2023-10-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 463 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-07-31
• Study Completion Date: 2017-04-30

Brief Summary

A Phase 2, Randomized, Pilot Study to Investigate the Safety, Efficacy, Pharmacokinetics and Bioavailability of HTX-011, HTX-002, or HTX-009 Administered Via Injection and/or Topical Application Following Unilateral Open Inguinal Herniorrhaphy

Detailed Description

This study includes multiple formulations for formulation selection of the fixed-combination product and for the factorial design assessment of the contribution of each component. HTX-011 is the initial formulation studied (HTX-011-19). HTX-011A is the second formulation studied (HTX-011-49). HTX-011B is the final formulation studied (HTX-011-56), which was also included in subsequent Phase 2b and Phase 3 studies. For the factorial design assessment, HTX-002, a bupivacaine-only formulation in the same HTX-011 proprietary polymer, and HTX-009, a meloxicam-only formulation in the same HTX-011 proprietary polymer, were evaluated.

Conditions

Postoperative Pain

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Part A, Cohort A

HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg by injection.

Group Type: EXPERIMENTAL

HTX-011

Intervention Type: DRUG

HTX-011 (bupivacaine/meloxicam) by injection.

Part A, Cohort B

HTX-011(bupivacaine/meloxicam), 400 mg/12 mg by injection.

Group Type: EXPERIMENTAL

HTX-011

Intervention Type: DRUG

HTX-011 (bupivacaine/meloxicam) by injection.

Part A, Cohort C

HTX-011 (bupivacaine/meloxicam), 200 mg/6 mg by instillation.

Group Type: EXPERIMENTAL

HTX-011

Intervention Type: DRUG

HTX-011 (bupivacaine/meloxicam) by injection.

Part A, Cohort D

HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg by instillation.

Group Type: EXPERIMENTAL

HTX-011

Intervention Type: DRUG

HTX-011 (bupivacaine/meloxicam) by injection.

Part A, Cohort E

HTX-011 (bupivacaine/meloxicam), 400 mg/12 mg by injection and instillation (combination).

Group Type: EXPERIMENTAL

HTX-011

Intervention Type: DRUG

HTX-011 (bupivacaine/meloxicam) by injection.

Part A, Cohort F

Saline placebo by injection.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Saline placebo by injection.

Part B, Cohort A

HTX-011A (bupivacaine/meloxicam), 200 mg/6 mg by injection.

Group Type: EXPERIMENTAL

HTX-011A

Intervention Type: DRUG

HTX-011A (bupivacaine/meloxicam) by injection.

Part B, Cohort B

HTX-011A (bupivacaine/meloxicam) 400 mg12 mg by injection.

Group Type: EXPERIMENTAL

HTX-011A

Intervention Type: DRUG

HTX-011A (bupivacaine/meloxicam) by injection.

Part B, Cohort C

HTX-011B (bupivacaine/meloxicam), 200 mg/6 mg by injection.

Group Type: EXPERIMENTAL

HTX-011B

Intervention Type: DRUG

HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Part B, Cohort D

HTX-011B (bupivacaine/meloxicam), 400 mg/12 mg by injection.

Group Type: EXPERIMENTAL

HTX-011B

Intervention Type: DRUG

HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Part B, Cohort E

Saline placebo by injection.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Saline placebo by injection.

Part C, Cohort A

HTX-002, 200 mg by injection or instillation.

Group Type: EXPERIMENTAL

HTX-002

Intervention Type: DRUG

HTX-002, by injection or instillation (pooled).

Part B, Cohort F

HTX-002, 400 mg by injection or instillation.

Group Type: EXPERIMENTAL

HTX-002

Intervention Type: DRUG

HTX-002, by injection or instillation (pooled).

Part C, Cohort B

HTX-011B (bupivacaine/meloxicam), 200 mg/6 mg by instillation.

Group Type: EXPERIMENTAL

HTX-011B

Intervention Type: DRUG

HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Part B, Cohort G

HTX-011B (bupivacaine/meloxicam), 400 mg/12 mg by instillation.

Group Type: EXPERIMENTAL

HTX-011B

Intervention Type: DRUG

HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Part C, Cohort C

Saline placebo by instillation.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Saline placebo by injection.

Part C, Cohort D

Bupivacaine HCI (Marcaine), 75 mg by injection.

Group Type: ACTIVE_COMPARATOR

Bupivacaine HCI (Marcaine)

Intervention Type: DRUG

Bupivacaine HCI (Marcaine) by injection.

Part D, Cohort A

HTX-011B (bupivacaine/meloxicam), 400 mg/13 mg via a combination of injection and instillation.

Group Type: EXPERIMENTAL

HTX-011B

Intervention Type: DRUG

HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Part E, Cohort A

HTX-009, 12 mg by injection and instillation (combination).

Group Type: EXPERIMENTAL

HTX-009

Intervention Type: DRUG

HTX-009 by injection and instillation (combination).

Part F, Cohort A

HTX-011B (bupivacaine/meloxicam), 300 mg/9 mg by instillation.

Group Type: EXPERIMENTAL

HTX-011B

Intervention Type: DRUG

HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Part F, Cohort B

Bupivacaine HCI (Marcaine), 75 mg by injection.

Group Type: EXPERIMENTAL

Bupivacaine HCI (Marcaine)

Intervention Type: DRUG

Bupivacaine HCI (Marcaine) by injection.

Part F, Cohort C

Saline placebo by injection.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Saline placebo by injection.

Interventions

HTX-011

HTX-011 (bupivacaine/meloxicam) by injection.

Intervention Type: DRUG

Placebo

Saline placebo by injection.

Intervention Type: DRUG

HTX-002

HTX-002, by injection or instillation (pooled).

Intervention Type: DRUG

Bupivacaine HCI (Marcaine)

Bupivacaine HCI (Marcaine) by injection.

Intervention Type: DRUG

HTX-011A

HTX-011A (bupivacaine/meloxicam) by injection.

Intervention Type: DRUG

HTX-011B

HTX-011B (bupivacaine/meloxicam) by injection, instillation or combination.

Intervention Type: DRUG

HTX-009

HTX-009 by injection and instillation (combination).

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Be male or female 18 years of age or older.

2. Female subjects are eligible only if all of the following apply:

Not pregnant (female subject of child bearing potential must have a negative serum pregnancy test at screening and negative urine pregnancy test before surgery)

• Not lactating
• Not planning to become pregnant during the study
• Be surgically sterile; or at least two years post-menopausal; or have a monogamous partner who is surgically sterile; or is practicing double-barrier contraception; or practicing abstinence (must agree to use double-barrier contraception in the event of sexual activity); or using an insertable, injectable, transdermal, or combination oral contraceptive approved by the FDA for greater than 2 months prior to screening visits and commits to the use of an acceptable form of birth control for the duration of the study and for 30 days from completion of the study

Male:

o Must be surgically sterile (biologically or surgically) or commit to the use of a reliable method of birth control for the duration of the study until at least 1 week after the administration of study medication.

3. Plan to undergo a unilateral inguinal herniorrhaphy

4. Have the ability and be willing to comply with the study procedures

5. Must be able to understand study procedures and give informed consent for the conduct for all study procedures, using an IRB approved consent form.

Exclusion Criteria

1. Unwilling to sign informed consent or not willing or able to complete all study procedures

2. Have a contraindication or be allergic to any medication to be used during the trial period

3. Have clinically significant cardiac abnormalities, that in the opinion of the investigator would pose a health risk to the subject should they participate in the trial

4. Have American Society of Anesthesiologists (ASA) Physical Status classification system category 4 or greater (Appendix E)

5. Have clinically significant renal or hepatic abnormalities (defined as an AST or ALT > 3x ULN, creatinine > 2x ULN)

6. Have another painful condition that may confound pain assessments

7. Have another surgery planned within 30 days of procedure, or presents with bilateral or recurrent inguinal hernia, other hernia presentations, or hernias with large scrotal component that would be difficult to reduce surgically

8. Have a known or suspected history of alcohol or drug abuse, or a positive drug screen

9. Currently taking analgesics for a chronically painful condition, or has taken long acting opioids within 3 days of surgery, or taken any opioids within 24 hours of surgery

10. Subjects with documented sleep apnea or are on home continuous positive airway pressure (CPAP)

11. Female subjects who are pregnant (positive pregnancy test at screening or on the day of surgery)

12. Subjects who are receiving oxygen therapy at the time of screening

13. Have participated in a clinical trial within 30 days of planned surgery

14. Have a body mass index (BMI) > 39 kg/m2

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Heron Therapeutics

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Anaheim, California, United States

Houston, Texas, United States

Houston, Texas, United States

Countries

United States

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

HTX-011-C2015-202

Identifier Type: -

Identifier Source: org_study_id